<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057849</url>
  </required_header>
  <id_info>
    <org_study_id>2007BAI17B04</org_study_id>
    <nct_id>NCT01057849</nct_id>
  </id_info>
  <brief_title>Standard Comprehensive Intervention to Treat First-episode Schizophrenia</brief_title>
  <official_title>Sequenced Atypical Antipsychotics Therapy With Intensive or Basic Psychosocial Intervention for First-episode Schizophrenia: An Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the PeopleÂ´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical
      antipsychotics are widely used since 1990s' in China. Although their efficacy for acute phase
      are all better than typicals, individulized regimen of them for first-episode schizophrenia
      and their effectiveness in real naturalistic clinical settings still remain unclear. And
      those patients also need more comprehensive intervention such as psychosocial programs to
      improve their function. This protocol is to conduct a study in several sites of China to
      investigate the effectiveness of comprehensive intervention combining sequenced atypical
      antipsychotic therapy and intensive psychosocial intervention for first-episode schizophrenic
      patients. In addition, this protocol also aims at collecting such information as molecular
      genetics, neurochemical test, neucognitive performance and neuroimaging for outcome analysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the time the patients remain stable</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scoring of PANSS and PSP</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Risperidone, Intensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risperidone and intensive psychosocial intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone, basic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>risperidone and basic psychosocial support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine, intensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine and intensive psychosocial intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine, basic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olanzapine and basic psychosocial support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole, intensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aripiprazole and intensive psychosocial intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole, basiv</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aripiprazole and basic psychosocial support</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>3-6 mg per day</description>
    <arm_group_label>Risperidone, Intensive</arm_group_label>
    <arm_group_label>risperidone, basic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>5-20 mg per day</description>
    <arm_group_label>olanzapine, intensive</arm_group_label>
    <arm_group_label>olanzapine, basic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>10-30 mg per day</description>
    <arm_group_label>aripiprazole, intensive</arm_group_label>
    <arm_group_label>aripiprazole, basiv</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  schizophrenic patients diagnosed with DSM-IV criteria by SCID-I.

          -  age between 16-45 years old

          -  with disease course less than 3 years and during their first episode

          -  without receiving systematic antipsychotic treatment less than 1 month

        Exclusion Criteria:

          -  organic disease or unstable physical diseases.

          -  brain trauma with loss of consciousness more than 1 hour

          -  current substance misuse (in 3 months) or any substance dependence.

          -  pregnant women.

          -  patients with severe suicidal imaginations or behavior.

          -  mental retardation

          -  contradict to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Yu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanbo Yuan, M.D.</last_name>
    <phone>+8613910821507</phone>
    <email>yuanyb@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anding Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhou</last_name>
      <email>pretty_zhouyan@126.com</email>
    </contact>
    <investigator>
      <last_name>Chuanyue Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fuchun Zhou, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Huilongguan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Chen, M.D.</last_name>
      <email>asongsi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fude Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yunlong Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Institute of Mental Health</name>
      <address>
        <city>Haidian District</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanbo Yuan, M.D.</last_name>
      <phone>+86-10-82806157</phone>
      <email>yuanyb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yanbo Yuan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongnan University Xiangya Second Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maorong Hu, M.D.</last_name>
      <email>maron13@126.com</email>
    </contact>
    <investigator>
      <last_name>Jingping Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lehua Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu, M.D.</last_name>
      <email>lnmilk-1982@126.com</email>
    </contact>
    <investigator>
      <last_name>Zheng Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianhua Sheng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan University Huaxi Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanming Liu, M.D.</last_name>
      <email>lciauo@sina.com</email>
    </contact>
    <investigator>
      <last_name>Hong Deng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shanming Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Xin Yu</name_title>
    <organization>Peking University Institute of Mental Health</organization>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>first episode</keyword>
  <keyword>atypical antipsychotics</keyword>
  <keyword>psychosocial intervention</keyword>
  <keyword>outcome</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

